Hemodialysis Prescription
By
Mohammed Kamal Nassar, MD
Lecturer of Nephrology
Mansoura University
Hemodialysis Circuit
Vascular
Access
J Am Soc Nephrol 24: 465–473, 2013
DIFFUSION
DIFFUSION
The rate of movement will depend on:
- The concentration gradient
- Membrane permeability
- Membrane Surface area
- Blood proteins
- The size of the solute
DIFFUSION
HYDROSTATIC
ULTRAFILTRATION
Dialyzers specification
High flux vs low flux
N Engl J Med 2002;347:2010-9
EGE studyHEMO trial
J Am Soc Nephrol 2013
Am J Kidney Dis. 2015;66(5):884-930
Anticoagulation
• Anticoagulation-free treatment: frequent saline flushes
• Unfractionated heparin
• Low-molecular-weight heparins
• Direct thrombin inhibitors
• Regional anticoagulation with citrate or prostacyclin
Unfractionated Heparin
Routine heparin, repeated-bolus method Routine heparin, constant-infusion method
Initial bolus dose (4,000 units). Initial bolus dose (2,000 units)
1,000 - 2,000-unit bolus dose when needed. Infusion at a rate of 1,200 units per hour.
at start of each hour1,000 Stopping infusion 1 hour prior to the end of
dialysis
With venous catheters, continue to the end
of dialysis
Low molecular weight heparin
Dialysis Prescription
• Dialysis Modality
• Dialysis frequency
• Dialysis duration
• Dialysis dose
• Dialysate:
ļ‚§ Sodium
ļ‚§ Potassium
ļ‚§ Calcium
ļ‚§ Bicarbonate
ļ‚§ Temperature
• Ideal body weight (IBW)
• Initial HD prescription
• Chronic HD prescription
Dialysis Prescription
• Dialysis Modality
• Dialysis frequency
• Dialysis duration
• Dialysis dose
• Dialysate:
ļ‚§ Sodium
ļ‚§ Potassium
ļ‚§ Calcium
ļ‚§ Bicarbonate
ļ‚§ Temperature
• Ideal body weight (IBW)
• Initial HD prescription
• Chronic HD prescription
Dialysis modality
John et al. Chest 2007:132;1379-1388
Am J Kidney Dis. 2014;63(1):153-163
Blankestijn. JASN 2013;24(3):332–334.
Bottom: 16 – 18.8 L
Middle: 20.2 – 22 L
Top: 24.4 – 27.4 L
22
Dialysis Prescription
• Dialysis Modality
• Dialysis frequency
• Dialysis duration
• Dialysis dose
• Dialysate:
ļ‚§ Sodium
ļ‚§ Potassium
ļ‚§ Calcium
ļ‚§ Bicarbonate
ļ‚§ Temperature
• Ideal body weight (IBW)
• Initial HD prescription
• Chronic HD prescription
Dialysis Frequency
Am J Kidney Dis. 2015;66(5):884-930
Hemodialysis six times per week (frequent hemodialysis, 125 patients) or
Three times per week (conventional hemodialysis, 120 patients)
For 12 months
Am J Kidney Dis. 2015;66(5):884-930
Dialysis Prescription
• Dialysis Modality
• Dialysis frequency
• Dialysis duration
• Dialysis dose
• Dialysate:
ļ‚§ Sodium
ļ‚§ Potassium
ļ‚§ Calcium
ļ‚§ Bicarbonate
ļ‚§ Temperature
• Ideal body weight (IBW)
• Initial HD prescription
• Chronic HD prescription
Dialysis duration
Am J Kidney Dis. 2015;66(5):884-930
Cohort study
1206: thrice weekly extended-hours hemodialysis
or
111,707: receiving conventional hemodialysis treatments.
Kidney International (2016)
All-cause mortality
Patients treated with extended-hours hemodialysis had a 33% lower adjusted
risk of death compared to those who were treated with a conventional
regimen (95% confidence interval: 7% to 51%).
Kidney International (2016)
Kidney International (2016) 90, 1146–1163
Dialysis Prescription
• Dialysis Modality
• Dialysis frequency
• Dialysis duration
•Dialysis dose
• Dialysate:
ļ‚§ Sodium
ļ‚§ Potassium
ļ‚§ Calcium
ļ‚§ Bicarbonate
ļ‚§ Temperature
• Ideal body weight (IBW)
• Initial HD prescription
• Chronic HD prescription
Dialysis Dose
Am J Kidney Dis. 2015;66(5):884-930
N Engl J Med 2002;347:2010-9
HEMO trial
Am J Kidney Dis. 2014;63(1):153-163
The three major determinants of urea clearance
during hemodialysis are:
1.Blood flow rate (Qb).
2.Dialysate flow rate (Qd).
3.Membrane (dialyzer) efficiency.
Dialysis Prescription
• Dialysis Modality
• Dialysis frequency
• Dialysis duration
• Dialysis dose
• Dialysate:
ļ‚§ Sodium
ļ‚§ Potassium
ļ‚§ Calcium
ļ‚§ Bicarbonate
ļ‚§ Temperature
• Ideal body weight (IBW)
• Initial HD prescription
• Chronic HD prescription
Dialysate
Dialysis Prescription
• Dialysis Modality
• Dialysis frequency
• Dialysis duration
• Dialysis dose
• Dialysate:
ļ‚§Sodium
ļ‚§ Potassium
ļ‚§ Calcium
ļ‚§ Bicarbonate
ļ‚§ Temperature
• Ideal body weight (IBW)
• Initial HD prescription
• Chronic HD prescription
Sodium
Clin J Am Soc Nephrol 7: 92–100, 2012.
Clin J Am Soc Nephrol 7: 92–100, 2012.
11,555 patients
Am J Kidney Dis. 2012;59(2):238-248
ā€œWe present the case of a patient who presented with renal failure requiring
dialysis and also with a serum Na of 112 mEq/l. Using a dialysate Na
concentration of 130 mEq/l and by limiting the blood flow to 50 ml/minute,
we were able to raise her serum Na by only 2 mEq/l/hour during her
hemodialysis treatment and thus control both the rate and total change in
the patient’s serum Na.ā€
Seminars in Dialysis, 2012;25:82-85
Effect of lowering dialysate Na on BP
Am J Kidney Dis. 2015;66(5):884-930
Dialysis Prescription
• Dialysis Modality
• Dialysis frequency
• Dialysis duration
• Dialysis dose
• Dialysate:
ļ‚§ Sodium
ļ‚§Potassium
ļ‚§ Calcium
ļ‚§ Bicarbonate
ļ‚§ Temperature
• Ideal body weight (IBW)
• Initial HD prescription
• Chronic HD prescription
Potassium
• The range of most commonly used dialysate concentrations is 2-4
mEq/L.
• Lower concentrations can be used in the setting of life-threatening
acute hyperkalemia, but only with extreme caution and frequent
intradialytic potassium measurements.
• There is no absolute recommended predialysis potassium level.
Better survival is associated with predialysis serum potassium
levels of 4.6-5.3 mEq/L.
Am J Kidney Dis. 2014;63(1):153-163
Dialysis Prescription
• Dialysis Modality
• Dialysis frequency
• Dialysis duration
• Dialysis dose
• Dialysate:
ļ‚§ Sodium
ļ‚§ Potassium
ļ‚§Calcium
ļ‚§ Bicarbonate
ļ‚§ Temperature
• Ideal body weight (IBW)
• Initial HD prescription
• Chronic HD prescription
Calcium
Kidney International (2009) 76 (Suppl 113)
Dialysis Prescription
• Dialysis Modality
• Dialysis frequency
• Dialysis duration
• Dialysis dose
• Dialysate:
ļ‚§ Sodium
ļ‚§ Potassium
ļ‚§ Calcium
ļ‚§Bicarbonate
ļ‚§ Temperature
• Ideal body weight (IBW)
• Initial HD prescription
• Chronic HD prescription
Am J Kidney Dis. 2013;62(4):738-746
Clin J Am Soc Nephrol 8: 254–264, 2013
Target pre-HD HCO3: >22 mmol/l, avoid severe
post-HD alkalosis
Dialysis Prescription
• Dialysis Modality
• Dialysis frequency
• Dialysis duration
• Dialysis dose
• Dialysate:
ļ‚§ Sodium
ļ‚§ Potassium
ļ‚§ Calcium
ļ‚§ Bicarbonate
ļ‚§Temperature
• Ideal body weight (IBW)
• Initial HD prescription
• Chronic HD prescription
Cool dialysate
Clin J Am Soc Nephrol 11: 442–457, 2016
Intradialytic hypotension
Clin J Am Soc Nephrol 11: 442–457, 2016
Change in mean arterial pressure
Clin J Am Soc Nephrol 11: 442–457, 2016
Symptoms of discomfort
Clin J Am Soc Nephrol 11: 442–457, 2016
Dialysis adequacy
Clin J Am Soc Nephrol 11: 442–457, 2016
Dialysis Prescription
• Dialysis Modality
• Dialysis frequency
• Dialysis duration
• Dialysis dose
• Dialysate:
ļ‚§ Sodium
ļ‚§ Potassium
ļ‚§ Calcium
ļ‚§ Bicarbonate
ļ‚§ Temperature
•Ideal body weight (IBW)
• Initial HD prescription
• Chronic HD prescription
IDWG
Clin J Am Soc Nephrol 2013.
Dialysis Prescription
• Dialysis Modality
• Dialysis frequency
• Dialysis duration
• Dialysis dose
• Dialysate:
ļ‚§ Sodium
ļ‚§ Potassium
ļ‚§ Calcium
ļ‚§ Bicarbonate
ļ‚§ Temperature
• Ideal body weight (IBW)
• Initial HD prescription
• Chronic HD prescription
Initial HD prescription
• Reduce 1st HD treatment time especially if serum urea level
is very high e.g. >240 mg/dL.
• A 2-hr session is recommended.
• Aim at URR of <40%.
• Subsequent session length can be gradually increased to a
standard of 4-5 hrs.
Dialysis Prescription
• Dialysis Modality
• Dialysis frequency
• Dialysis duration
• Dialysis dose
• Dialysate:
ļ‚§ Sodium
ļ‚§ Potassium
ļ‚§ Calcium
ļ‚§ Bicarbonate
ļ‚§ Temperature
• Ideal body weight (IBW)
• Initial HD prescription
• Chronic HD prescription
Various HD prescriptions
Am J Kidney Dis. 2015;66(5):884-930
The three major determinants of urea clearance
during hemodialysis are:
1.Blood flow rate (Qb).
2.Dialysate flow rate (Qd).
3.Membrane (dialyzer) efficiency.
Adequate Vs Optimal Dialysis
Conclusion
Basic criteria to be met
by adequate dialysis
• Fluid removal permitting return to correctly evaluated 'dry weight' at end of
dialysis.
• Predialysis blood pressure < 140/90 mmHg with or without antihypertensive drugs.
• Predialysis plasma concentrations :
ļ‚§ Potassium: < 5.5 mmol/l without adsorption of ion exchange resins.
ļ‚§ Bicarbonate: >22 mmol/l .
ļ‚§ Inorganic phosphate: < 5.5 mg/dl without oral binding agents.
ļ‚§ Urea: < 35 mmol/l with daily protein-intake 1.2 g/kg/BW .
ļ‚§ Albumin: > 4 g/dl .
ļ‚§ Hemoglobin: 10–11.5 g/dl with or without rHu-EPO.
Technical requirements for
delivery of adequate dialysis
• Vascular access: blood flow ≄ 300 ml/min .
• Dialysis fluid: bicarbonate buffered, sterile, pyrogen-free, QD: ≄500 ml/min.
• Volumetric ultrafiltration control.
• Dialyzer:
ļ‚§ Highly permeable, biocompatible membrane.
ļ‚§ Surface area: suitable.
• Dose of dialysis:
ļ‚§ Minimum Kt/V urea: 1.2–1.3 (single pool).
ļ‚§ Minimum urea reduction rate: 65–70%.
ļ‚§ Weekly dialysis time: ≄12 h (4–4.5 h Ɨ 3) .
Criteria for Optimal Dialysis
1.Normalized blood pressure with minimal antihypertensive
medications.
2.Normalized calcium-phosphate product with neither phosphate
binders nor phosphate supplements.
3.An absence of intradialytic symptoms such as hypotension, cramps,
and nausea.
4.An absence of interdialytic symptoms.
5.No interference with ability to hold a job.
6.Protein appetite under the patient's free will.
7.Neither alkalotic nor acidotic.
8.No evidence of left ventricular hypertrophy.
9. Hematocrit in the 35-to-38 range with the use of at least 50% or
less of today's average erythropoietin dose.
10. No dialysis-related or access-related hospitalizations.
11. Normal triglyceride level.
12. No evidence of amyloidosis.
13. The longest preservation of residual kidney function.
14. Life expectancy approximately that of living-related-donor
transplants.
15. Inflammation near normal.
Criteria for Optimal Dialysis
"Adequate" Kt/V Does Not Provide "Optimal" Dialysis
Kt/V Should be a Means, Not a Goal
Thank You

Hd Prescription

  • 1.
    Hemodialysis Prescription By Mohammed KamalNassar, MD Lecturer of Nephrology Mansoura University
  • 2.
  • 3.
  • 5.
    J Am SocNephrol 24: 465–473, 2013
  • 9.
  • 10.
  • 11.
    The rate ofmovement will depend on: - The concentration gradient - Membrane permeability - Membrane Surface area - Blood proteins - The size of the solute DIFFUSION
  • 12.
  • 13.
  • 14.
    High flux vslow flux
  • 15.
    N Engl JMed 2002;347:2010-9 EGE studyHEMO trial J Am Soc Nephrol 2013
  • 16.
    Am J KidneyDis. 2015;66(5):884-930
  • 18.
    Anticoagulation • Anticoagulation-free treatment:frequent saline flushes • Unfractionated heparin • Low-molecular-weight heparins • Direct thrombin inhibitors • Regional anticoagulation with citrate or prostacyclin
  • 19.
    Unfractionated Heparin Routine heparin,repeated-bolus method Routine heparin, constant-infusion method Initial bolus dose (4,000 units). Initial bolus dose (2,000 units) 1,000 - 2,000-unit bolus dose when needed. Infusion at a rate of 1,200 units per hour. at start of each hour1,000 Stopping infusion 1 hour prior to the end of dialysis With venous catheters, continue to the end of dialysis
  • 20.
  • 22.
    Dialysis Prescription • DialysisModality • Dialysis frequency • Dialysis duration • Dialysis dose • Dialysate: ļ‚§ Sodium ļ‚§ Potassium ļ‚§ Calcium ļ‚§ Bicarbonate ļ‚§ Temperature • Ideal body weight (IBW) • Initial HD prescription • Chronic HD prescription
  • 23.
    Dialysis Prescription • DialysisModality • Dialysis frequency • Dialysis duration • Dialysis dose • Dialysate: ļ‚§ Sodium ļ‚§ Potassium ļ‚§ Calcium ļ‚§ Bicarbonate ļ‚§ Temperature • Ideal body weight (IBW) • Initial HD prescription • Chronic HD prescription
  • 24.
  • 25.
    John et al.Chest 2007:132;1379-1388
  • 26.
    Am J KidneyDis. 2014;63(1):153-163
  • 27.
  • 31.
    Bottom: 16 –18.8 L Middle: 20.2 – 22 L Top: 24.4 – 27.4 L
  • 32.
  • 33.
    Dialysis Prescription • DialysisModality • Dialysis frequency • Dialysis duration • Dialysis dose • Dialysate: ļ‚§ Sodium ļ‚§ Potassium ļ‚§ Calcium ļ‚§ Bicarbonate ļ‚§ Temperature • Ideal body weight (IBW) • Initial HD prescription • Chronic HD prescription
  • 34.
    Dialysis Frequency Am JKidney Dis. 2015;66(5):884-930
  • 35.
    Hemodialysis six timesper week (frequent hemodialysis, 125 patients) or Three times per week (conventional hemodialysis, 120 patients) For 12 months
  • 36.
    Am J KidneyDis. 2015;66(5):884-930
  • 37.
    Dialysis Prescription • DialysisModality • Dialysis frequency • Dialysis duration • Dialysis dose • Dialysate: ļ‚§ Sodium ļ‚§ Potassium ļ‚§ Calcium ļ‚§ Bicarbonate ļ‚§ Temperature • Ideal body weight (IBW) • Initial HD prescription • Chronic HD prescription
  • 38.
    Dialysis duration Am JKidney Dis. 2015;66(5):884-930
  • 39.
    Cohort study 1206: thriceweekly extended-hours hemodialysis or 111,707: receiving conventional hemodialysis treatments. Kidney International (2016)
  • 40.
    All-cause mortality Patients treatedwith extended-hours hemodialysis had a 33% lower adjusted risk of death compared to those who were treated with a conventional regimen (95% confidence interval: 7% to 51%). Kidney International (2016)
  • 41.
    Kidney International (2016)90, 1146–1163
  • 42.
    Dialysis Prescription • DialysisModality • Dialysis frequency • Dialysis duration •Dialysis dose • Dialysate: ļ‚§ Sodium ļ‚§ Potassium ļ‚§ Calcium ļ‚§ Bicarbonate ļ‚§ Temperature • Ideal body weight (IBW) • Initial HD prescription • Chronic HD prescription
  • 43.
    Dialysis Dose Am JKidney Dis. 2015;66(5):884-930
  • 44.
    N Engl JMed 2002;347:2010-9 HEMO trial
  • 45.
    Am J KidneyDis. 2014;63(1):153-163
  • 46.
    The three majordeterminants of urea clearance during hemodialysis are: 1.Blood flow rate (Qb). 2.Dialysate flow rate (Qd). 3.Membrane (dialyzer) efficiency.
  • 47.
    Dialysis Prescription • DialysisModality • Dialysis frequency • Dialysis duration • Dialysis dose • Dialysate: ļ‚§ Sodium ļ‚§ Potassium ļ‚§ Calcium ļ‚§ Bicarbonate ļ‚§ Temperature • Ideal body weight (IBW) • Initial HD prescription • Chronic HD prescription
  • 48.
  • 49.
    Dialysis Prescription • DialysisModality • Dialysis frequency • Dialysis duration • Dialysis dose • Dialysate: ļ‚§Sodium ļ‚§ Potassium ļ‚§ Calcium ļ‚§ Bicarbonate ļ‚§ Temperature • Ideal body weight (IBW) • Initial HD prescription • Chronic HD prescription
  • 50.
    Sodium Clin J AmSoc Nephrol 7: 92–100, 2012.
  • 51.
    Clin J AmSoc Nephrol 7: 92–100, 2012.
  • 52.
    11,555 patients Am JKidney Dis. 2012;59(2):238-248
  • 53.
    ā€œWe present thecase of a patient who presented with renal failure requiring dialysis and also with a serum Na of 112 mEq/l. Using a dialysate Na concentration of 130 mEq/l and by limiting the blood flow to 50 ml/minute, we were able to raise her serum Na by only 2 mEq/l/hour during her hemodialysis treatment and thus control both the rate and total change in the patient’s serum Na.ā€ Seminars in Dialysis, 2012;25:82-85
  • 54.
    Effect of loweringdialysate Na on BP Am J Kidney Dis. 2015;66(5):884-930
  • 55.
    Dialysis Prescription • DialysisModality • Dialysis frequency • Dialysis duration • Dialysis dose • Dialysate: ļ‚§ Sodium ļ‚§Potassium ļ‚§ Calcium ļ‚§ Bicarbonate ļ‚§ Temperature • Ideal body weight (IBW) • Initial HD prescription • Chronic HD prescription
  • 56.
    Potassium • The rangeof most commonly used dialysate concentrations is 2-4 mEq/L. • Lower concentrations can be used in the setting of life-threatening acute hyperkalemia, but only with extreme caution and frequent intradialytic potassium measurements. • There is no absolute recommended predialysis potassium level. Better survival is associated with predialysis serum potassium levels of 4.6-5.3 mEq/L. Am J Kidney Dis. 2014;63(1):153-163
  • 57.
    Dialysis Prescription • DialysisModality • Dialysis frequency • Dialysis duration • Dialysis dose • Dialysate: ļ‚§ Sodium ļ‚§ Potassium ļ‚§Calcium ļ‚§ Bicarbonate ļ‚§ Temperature • Ideal body weight (IBW) • Initial HD prescription • Chronic HD prescription
  • 58.
  • 59.
    Dialysis Prescription • DialysisModality • Dialysis frequency • Dialysis duration • Dialysis dose • Dialysate: ļ‚§ Sodium ļ‚§ Potassium ļ‚§ Calcium ļ‚§Bicarbonate ļ‚§ Temperature • Ideal body weight (IBW) • Initial HD prescription • Chronic HD prescription
  • 60.
    Am J KidneyDis. 2013;62(4):738-746
  • 61.
    Clin J AmSoc Nephrol 8: 254–264, 2013
  • 62.
    Target pre-HD HCO3:>22 mmol/l, avoid severe post-HD alkalosis
  • 63.
    Dialysis Prescription • DialysisModality • Dialysis frequency • Dialysis duration • Dialysis dose • Dialysate: ļ‚§ Sodium ļ‚§ Potassium ļ‚§ Calcium ļ‚§ Bicarbonate ļ‚§Temperature • Ideal body weight (IBW) • Initial HD prescription • Chronic HD prescription
  • 64.
    Cool dialysate Clin JAm Soc Nephrol 11: 442–457, 2016
  • 65.
    Intradialytic hypotension Clin JAm Soc Nephrol 11: 442–457, 2016
  • 66.
    Change in meanarterial pressure Clin J Am Soc Nephrol 11: 442–457, 2016
  • 67.
    Symptoms of discomfort ClinJ Am Soc Nephrol 11: 442–457, 2016
  • 68.
    Dialysis adequacy Clin JAm Soc Nephrol 11: 442–457, 2016
  • 69.
    Dialysis Prescription • DialysisModality • Dialysis frequency • Dialysis duration • Dialysis dose • Dialysate: ļ‚§ Sodium ļ‚§ Potassium ļ‚§ Calcium ļ‚§ Bicarbonate ļ‚§ Temperature •Ideal body weight (IBW) • Initial HD prescription • Chronic HD prescription
  • 70.
    IDWG Clin J AmSoc Nephrol 2013.
  • 72.
    Dialysis Prescription • DialysisModality • Dialysis frequency • Dialysis duration • Dialysis dose • Dialysate: ļ‚§ Sodium ļ‚§ Potassium ļ‚§ Calcium ļ‚§ Bicarbonate ļ‚§ Temperature • Ideal body weight (IBW) • Initial HD prescription • Chronic HD prescription
  • 74.
    Initial HD prescription •Reduce 1st HD treatment time especially if serum urea level is very high e.g. >240 mg/dL. • A 2-hr session is recommended. • Aim at URR of <40%. • Subsequent session length can be gradually increased to a standard of 4-5 hrs.
  • 75.
    Dialysis Prescription • DialysisModality • Dialysis frequency • Dialysis duration • Dialysis dose • Dialysate: ļ‚§ Sodium ļ‚§ Potassium ļ‚§ Calcium ļ‚§ Bicarbonate ļ‚§ Temperature • Ideal body weight (IBW) • Initial HD prescription • Chronic HD prescription
  • 76.
    Various HD prescriptions AmJ Kidney Dis. 2015;66(5):884-930
  • 77.
    The three majordeterminants of urea clearance during hemodialysis are: 1.Blood flow rate (Qb). 2.Dialysate flow rate (Qd). 3.Membrane (dialyzer) efficiency.
  • 81.
    Adequate Vs OptimalDialysis Conclusion
  • 82.
    Basic criteria tobe met by adequate dialysis • Fluid removal permitting return to correctly evaluated 'dry weight' at end of dialysis. • Predialysis blood pressure < 140/90 mmHg with or without antihypertensive drugs. • Predialysis plasma concentrations : ļ‚§ Potassium: < 5.5 mmol/l without adsorption of ion exchange resins. ļ‚§ Bicarbonate: >22 mmol/l . ļ‚§ Inorganic phosphate: < 5.5 mg/dl without oral binding agents. ļ‚§ Urea: < 35 mmol/l with daily protein-intake 1.2 g/kg/BW . ļ‚§ Albumin: > 4 g/dl . ļ‚§ Hemoglobin: 10–11.5 g/dl with or without rHu-EPO.
  • 83.
    Technical requirements for deliveryof adequate dialysis • Vascular access: blood flow ≄ 300 ml/min . • Dialysis fluid: bicarbonate buffered, sterile, pyrogen-free, QD: ≄500 ml/min. • Volumetric ultrafiltration control. • Dialyzer: ļ‚§ Highly permeable, biocompatible membrane. ļ‚§ Surface area: suitable. • Dose of dialysis: ļ‚§ Minimum Kt/V urea: 1.2–1.3 (single pool). ļ‚§ Minimum urea reduction rate: 65–70%. ļ‚§ Weekly dialysis time: ≄12 h (4–4.5 h Ɨ 3) .
  • 84.
    Criteria for OptimalDialysis 1.Normalized blood pressure with minimal antihypertensive medications. 2.Normalized calcium-phosphate product with neither phosphate binders nor phosphate supplements. 3.An absence of intradialytic symptoms such as hypotension, cramps, and nausea. 4.An absence of interdialytic symptoms. 5.No interference with ability to hold a job. 6.Protein appetite under the patient's free will. 7.Neither alkalotic nor acidotic. 8.No evidence of left ventricular hypertrophy.
  • 85.
    9. Hematocrit inthe 35-to-38 range with the use of at least 50% or less of today's average erythropoietin dose. 10. No dialysis-related or access-related hospitalizations. 11. Normal triglyceride level. 12. No evidence of amyloidosis. 13. The longest preservation of residual kidney function. 14. Life expectancy approximately that of living-related-donor transplants. 15. Inflammation near normal. Criteria for Optimal Dialysis
  • 87.
    "Adequate" Kt/V DoesNot Provide "Optimal" Dialysis Kt/V Should be a Means, Not a Goal
  • 88.

Editor's Notes

  • #6Ā persons using catheters for hemodialysis seem to have the highest risks for death, infections, and cardiovascular events compared with other vascular access types, and patients with usable fistulas have the lowest risk.
  • #16Ā Patients undergoing hemodialysis thrice weekly appear to have no major benefit from a higher dialysis dose than that recommended by current U.S. guidelines or from the use of a high-flux membrane. EGE: In conclusion, this trial did not detect a difference in cardiovascular event-free survival between flux and dialysate groups. Posthoc analyses suggest that high-flux hemodialysis may benefit patients with an arteriovenous fistula and patients with diabetes and that ultrapure dialysate may benefit patients with longer dialysis vintage.
  • #32Ā Hazard ratios (HRs; boxes) and 95% confidence intervals (CIs; bars) for all-cause mortality in patients receiving online hemodiafiltration versus hemodialysis by convection volume, using different methods to standardize convection volume. Higher convection volumes were generally associated with greater survival benefit with OL-HDF, but results varied across different ways of standardization for body size. Thus, further studies should take body size into account when evaluating the impact of delivered convection volume on mortality end points.
  • #40Ā Thus, in this large nationally representative cohort, treatment with extendedhours hemodialysis was associated with a lower risk for mortality compared to treatment with conventional in-center therapy. Adequately powered randomized clinical trials comparing extended-hours to conventional hemodialysis are required to confirm these findings.
  • #41Ā Risks for all-cause mortality comparing extended-hours hemodialysis to conventional hemodialysis, by time period for dialysis modality death attribution
  • #45Ā Standard dose: Kt/V 1.3 High dose: Kt/V 1.7 Patients undergoing hemodialysis thrice weekly appear to have no major benefit from a higher dialysis dose than that recommended by current U.S. guidelines or from the use of a high-flux membrane.
  • #52Ā In the absence of randomized prospective studies, the benefit of reducing IDWGby decreasing DNa prescriptions should be carefully weighed against an increased risk for adverse outcomes.
  • #53Ā Lower serum sodium levels are associated with certain hemodialysis patient characteristics and higher adjusted risk of death. The lower mortality observed in our adjusted analyses in patients with serum sodium levels 137 mEq/L dialyzed against dialysate sodium prescriptions 140 mEq/L is intriguing, may be related to intradialytic cardiovascular stability, and deserves further study.
  • #61Ā High dialysate bicarbonate concentrations, especially prolonged exposure, may contribute to adverse outcomes, likely through the development of postdialysis metabolic alkalosis. Additional studies are warranted to identify the optimal dialysate bicarbonate concentration.
  • #62Ā The measured bicarbonate is significantly higher in peritoneal dialysis patients, suggesting that the therapy provides a more complete correction ofmetabolic acidosis than intermittent hemodialysis. Survival data suggest maintaining serum bicarbonate.22 mEq/L for all ESRD patients, irrespective of dialysis modality.
  • #65Ā In patients receiving chronic hemodialysis, reduced temperature dialysis may reduce the rate of intradialytic hypotension and increase intradialytic mean arterial pressure. High–quality, large, multicenter, randomized trials are needed to determine whether reduced temperature dialysis affects patient mortality and major adverse cardiovascular events.
  • #71Ā Among patients with adequate urea clearance, shorter dialysis session length and greater interdialytic weight gain are associated with increased mortality; thus, both are viable targets for directed intervention.